MA52569B1 - Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant - Google Patents
Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendantInfo
- Publication number
- MA52569B1 MA52569B1 MA52569A MA52569A MA52569B1 MA 52569 B1 MA52569 B1 MA 52569B1 MA 52569 A MA52569 A MA 52569A MA 52569 A MA52569 A MA 52569A MA 52569 B1 MA52569 B1 MA 52569B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- voltage
- potassium channel
- bioavailability
- exposure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Selon certains modes de réalisation, la présente invention concerne des procédés et des utilisations pour traiter des troubles épileptiques chez un être humain, les procédés et les utilisations comprenant l'administration par voie orale d'une quantité thérapeutiquement efficace du modulateur allostérique du canal potassique sensible à la tension, n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-diméthylphényl]-3,3- diméthylbutanamide (composé a), à l'homme en ayant besoin, par exemple, dans des conditions d'alimentation. La présente invention concerne en outre divers procédés améliorés de thérapie et d'administration du composé a.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670253P | 2018-05-11 | 2018-05-11 | |
| PCT/US2019/031872 WO2019217924A1 (fr) | 2018-05-11 | 2019-05-10 | Procédés d'amélioration de la biodisponibilité et de l'exposition d'un dispositif d'ouverture de canal potassique sensible à la tension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52569A MA52569A (fr) | 2021-03-17 |
| MA52569B1 true MA52569B1 (fr) | 2023-11-30 |
Family
ID=66669101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52569A MA52569B1 (fr) | 2018-05-11 | 2019-05-10 | Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant |
Country Status (34)
| Country | Link |
|---|---|
| US (6) | US11135214B2 (fr) |
| EP (2) | EP3790548B1 (fr) |
| JP (3) | JP7570924B2 (fr) |
| KR (1) | KR20210020892A (fr) |
| CN (3) | CN112384216A (fr) |
| AU (2) | AU2019265002C1 (fr) |
| BR (1) | BR112020022713A2 (fr) |
| CA (1) | CA3099292A1 (fr) |
| CL (1) | CL2020002932A1 (fr) |
| CO (1) | CO2020015476A2 (fr) |
| CR (1) | CR20200602A (fr) |
| DK (1) | DK3790548T3 (fr) |
| EA (1) | EA202092720A1 (fr) |
| ES (1) | ES2964409T3 (fr) |
| FI (1) | FI3790548T3 (fr) |
| GE (2) | GEP20237527B (fr) |
| HR (1) | HRP20231447T1 (fr) |
| HU (1) | HUE064326T2 (fr) |
| IL (2) | IL278577B2 (fr) |
| LT (1) | LT3790548T (fr) |
| MA (1) | MA52569B1 (fr) |
| MD (1) | MD3790548T2 (fr) |
| MX (2) | MX2020012008A (fr) |
| MY (1) | MY204915A (fr) |
| PE (1) | PE20211211A1 (fr) |
| PH (1) | PH12020551898A1 (fr) |
| PL (1) | PL3790548T3 (fr) |
| PT (1) | PT3790548T (fr) |
| RS (1) | RS64922B1 (fr) |
| SG (1) | SG11202011102TA (fr) |
| SI (1) | SI3790548T1 (fr) |
| SM (1) | SMT202300399T1 (fr) |
| UA (1) | UA127229C2 (fr) |
| WO (1) | WO2019217924A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52569B1 (fr) | 2018-05-11 | 2023-11-30 | Xenon Pharmaceuticals Inc | Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant |
| TWI886158B (zh) | 2019-10-10 | 2025-06-11 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| CA3155812A1 (fr) | 2019-11-08 | 2021-05-14 | Cynthia Louise HARDEN | Methodes de traitement de troubles depressifs |
| WO2021113757A1 (fr) * | 2019-12-06 | 2021-06-10 | Xenon Pharmaceuticals Inc. | Utilisation d'un agent d'ouverture du canal potassique kv7 pour le traitement de la douleur |
| GEAP202416349A (en) * | 2021-02-09 | 2024-02-12 | Xenon Pharmaceuticals Inc | Conjoint therapy for treating seizure disorders |
| TW202245744A (zh) | 2021-02-09 | 2022-12-01 | 加拿大商再諾製藥公司 | 治療失樂症之方法及用途 |
| CN113698345B (zh) * | 2021-10-27 | 2022-02-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的化合物及其制备和应用 |
| WO2026102345A1 (fr) | 2024-11-08 | 2026-05-15 | Xenon Pharmaceuticals Inc. | Méthodes d'administration de l'ouvreur de canal potassique voltage-dépendant azétukalnère |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| US8119602B2 (en) | 2005-06-02 | 2012-02-21 | Schering Corporation | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
| EP2012769A1 (fr) | 2006-05-02 | 2009-01-14 | Rundfeldt, Chris | Activateurs de canaux potassiques pour la prévention et le traitement de la dystonie et des systèmes assimilés à la dystonie |
| NZ575652A (en) | 2006-08-23 | 2011-08-26 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
| CA2787247A1 (fr) * | 2010-01-20 | 2011-07-28 | Glaxo Group Limited | Nouvelle composition |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| MA52569B1 (fr) | 2018-05-11 | 2023-11-30 | Xenon Pharmaceuticals Inc | Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant |
-
2019
- 2019-05-10 MA MA52569A patent/MA52569B1/fr unknown
- 2019-05-10 JP JP2020562201A patent/JP7570924B2/ja active Active
- 2019-05-10 CN CN201980046273.0A patent/CN112384216A/zh active Pending
- 2019-05-10 CN CN202510554905.1A patent/CN120549930A/zh active Pending
- 2019-05-10 PL PL19727216.4T patent/PL3790548T3/pl unknown
- 2019-05-10 PE PE2020001843A patent/PE20211211A1/es unknown
- 2019-05-10 EP EP19727216.4A patent/EP3790548B1/fr active Active
- 2019-05-10 SG SG11202011102TA patent/SG11202011102TA/en unknown
- 2019-05-10 CA CA3099292A patent/CA3099292A1/fr active Pending
- 2019-05-10 CN CN202510554824.1A patent/CN120549929A/zh active Pending
- 2019-05-10 EA EA202092720A patent/EA202092720A1/ru unknown
- 2019-05-10 KR KR1020207035334A patent/KR20210020892A/ko active Pending
- 2019-05-10 LT LTEPPCT/US2019/031872T patent/LT3790548T/lt unknown
- 2019-05-10 CR CR20200602A patent/CR20200602A/es unknown
- 2019-05-10 MX MX2020012008A patent/MX2020012008A/es unknown
- 2019-05-10 FI FIEP19727216.4T patent/FI3790548T3/fi active
- 2019-05-10 BR BR112020022713-7A patent/BR112020022713A2/pt unknown
- 2019-05-10 IL IL278577A patent/IL278577B2/en unknown
- 2019-05-10 GE GEAP201915508A patent/GEP20237527B/en unknown
- 2019-05-10 MY MYPI2020005869A patent/MY204915A/en unknown
- 2019-05-10 WO PCT/US2019/031872 patent/WO2019217924A1/fr not_active Ceased
- 2019-05-10 HR HRP20231447TT patent/HRP20231447T1/hr unknown
- 2019-05-10 PT PT197272164T patent/PT3790548T/pt unknown
- 2019-05-10 ES ES19727216T patent/ES2964409T3/es active Active
- 2019-05-10 SM SM20230399T patent/SMT202300399T1/it unknown
- 2019-05-10 DK DK19727216.4T patent/DK3790548T3/da active
- 2019-05-10 IL IL319015A patent/IL319015A/en unknown
- 2019-05-10 UA UAA202007781A patent/UA127229C2/uk unknown
- 2019-05-10 MD MDE20210233T patent/MD3790548T2/ro unknown
- 2019-05-10 EP EP23185386.2A patent/EP4279133A3/fr active Pending
- 2019-05-10 SI SI201930665T patent/SI3790548T1/sl unknown
- 2019-05-10 RS RS20231089A patent/RS64922B1/sr unknown
- 2019-05-10 GE GEAP202315508A patent/GEAP202315508A/en unknown
- 2019-05-10 AU AU2019265002A patent/AU2019265002C1/en active Active
- 2019-05-10 HU HUE19727216A patent/HUE064326T2/hu unknown
- 2019-05-13 US US16/410,851 patent/US11135214B2/en active Active
-
2020
- 2020-11-09 PH PH12020551898A patent/PH12020551898A1/en unknown
- 2020-11-10 MX MX2023013247A patent/MX2023013247A/es unknown
- 2020-11-11 CL CL2020002932A patent/CL2020002932A1/es unknown
- 2020-12-11 CO CONC2020/0015476A patent/CO2020015476A2/es unknown
-
2021
- 2021-10-01 US US17/449,785 patent/US20220062266A1/en not_active Abandoned
-
2024
- 2024-04-26 US US18/648,049 patent/US20240316032A1/en active Pending
- 2024-05-30 US US18/679,045 patent/US20240316033A1/en active Pending
- 2024-09-17 AU AU2024219794A patent/AU2024219794A1/en active Pending
- 2024-10-09 JP JP2024177074A patent/JP7793016B2/ja active Active
-
2025
- 2025-01-03 US US19/008,882 patent/US20250275957A1/en active Pending
- 2025-03-28 US US19/094,303 patent/US20250221980A1/en active Pending
- 2025-12-16 JP JP2025253235A patent/JP2026048849A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56607A1 (fr) | Méthodes de traitement de troubles dépressifs | |
| NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| MA48051B1 (fr) | Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide | |
| MA34474B1 (fr) | Agonistes de gpr40 | |
| MA30526B1 (fr) | Inhibiteurs de prolyle hydroxylase | |
| DE69534564D1 (de) | Verwendung von 2-hydroxy-5-phenylazobenzoesäure-derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| WO2003105800A3 (fr) | Forme galenique, se presentant sous forme de film adherant a la muqueuse, pour l'administration de principes actifs du cannabis | |
| EA200100958A1 (ru) | Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2 | |
| EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
| CO5590918A2 (es) | Formulaciones | |
| MA33552B1 (fr) | Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques | |
| DE60026155D1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
| DK1664016T3 (da) | Terapeutiske midler, der er anvendelige til behandling af smerter | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MY204915A (en) | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener | |
| DE69912930D1 (de) | Neue salzformn von (2e)-5-amino-5-methylhex-2-enolsäure n-methyl-n-((1r)-1-(methylcarbamoyl)-2-phruylrthyl) carbamoyl)-2-(2-naphtyl)ethyl)amid | |
| EA202190621A1 (ru) | Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты | |
| DK1284977T3 (da) | Thienodibenzoazulenforbindelser som tumornekrosefaktorhæmmere | |
| IN2005KO00312A (fr) | ||
| CY1109975T1 (el) | Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων | |
| TNSN06370A1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
| WO2001091796A8 (fr) | Methodes, composes et compositions permettant de traiter la goutte |